Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Nature Medicine

Volumn 22, Issue 3, 2016, Pages 262-269

  Hata, Aaron N ^a,b   Niederst, Matthew J ^a,b   Archibald, Hannah L ^a   Gomez Caraballo, Maria ^a   Siddiqui, Faria M ^a   Mulvey, Hillary E ^a   Maruvka, Yosef E ^a,c   Ji, Fei ^a   Bhang, Hyo Eun C ^d   Radhakrishna, Viveksagar Krishnamurthy ^d   Siravegna, Giulia ^e,f   Hu, Haichuan ^a   Raoof, Sana ^a,b   Lockerman, Elizabeth ^a   Kalsy, Anuj ^a   Lee, Dana ^a   Keating, Celina L ^d   Ruddy, David A ^d   Damon, Leah J ^a   Crystal, Adam S ^a,d   Costa, Carlotta ^a,b   Piotrowska, Zofia ^a,b   Bardelli, Alberto ^e,f   Iafrate, Anthony J ^a   Sadreyev, Ruslan I ^a   Stegmeier, Frank ^d   Getz, Gad ^a,b,c   Sequist, Lecia V ^a,b   Faber, Anthony C ^g,h   Engelman, Jeffrey A ^a,b   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD UNIVERSITY   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e UNIVERSITY OF TURIN   (Italy)

^f CANDIOLO CANCER INSTITUTE   (Italy)

^g VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^h VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; NAVITOCLAX; PROTEIN BCL 2; PROTEIN BCL XL; EGFR PROTEIN, HUMAN; MESSENGER RNA; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CLONE; CELL VIABILITY; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; MOLECULAR EVOLUTION; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR CELL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; IN VITRO STUDY; LUNG NEOPLASMS; METABOLISM; MUTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN VITRO TECHNIQUES; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84978619027     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4040     Document Type: Article

References (55)

1. Mok, T.S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957 (2009
2. Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380-2388 (2010
3. Camidge, D.R., Pao, W. & Sequist, L.V. Acquired resistance to TKIs in solid tumors: learning from lung cancer. Nat. Rev. Clin. Oncol. 11, 473-481 (2014
4. Sequist, L.V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011
5. Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005
6. Engelman, J.A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007
7. Turke, A.B. et al. Preexistence and clonal selection of MET amplification in EGFR-mutant NSCLC. Cancer Cell 17, 77-88 (2010
8. Bhang, H.E. et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat. Med. 21, 440-448 (2015
9. Su, K.Y. et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 30, 433-440 (2012
10. Ye, X. et al. High T790M detection rate in TKI-naive NSCLC with EGFR-sensitive mutation: truth or artifact?. J. Thorac. Oncol. 8, 1118-1120 (2013
11. Sharma, S.V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010
12. Lee, H.J. et al. Drug resistance via feedback activation of Stat3 in oncogene-Addicted cancer cells. Cancer Cell 26, 207-221 (2014
13. Wilson, T.R. et al. Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012
14. Crystal, A.S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480-1486 (2014
15. Zhou, W. et al. Novel mutant-selective EGFR kinase inhibitors against EGFRT790M. Nature 462, 1070-1074 (2009
16. Hata, A.N., Engelman, J.A. & Faber, A.C. The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discov. 5, 475-487 (2015
17. Cragg, M.S., Kuroda, J., Puthalakath, H., Huang, D.C. & Strasser, A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med. 4, 1681-1689, discussion 1690 (2007
18. Costa, D.B. et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 4, 1669-1679 discussion 1680 (2007
19. Gong, Y. et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med. 4, e294 2007
20. Faber, A.C. et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov. 1, 352-365 (2011
21. Robasky, K., Lewis, N.E. & Church, G.M. The role of replicates for error mitigation in next-generation sequencing. Nat. Rev. Genet. 15, 56-62 (2014
22. Hindson, B.J. et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal. Chem. 83, 8604-8610 (2011
23. Zheng, Z. et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat. Med. 20, 1479-1484 (2014
24. Ohashi, K. et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS or MEK1. Proc. Natl. Acad. Sci. USA 109, E2127-E2133 (2012
25. Eberlein, C.A. et al. Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res. 75, 2489-2500 (2015
26. Piotrowska, Z. et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov. 5, 713-722 (2015
27. Jänne, P.A. et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 372, 1689-1699 (2015
28. Sequist, L.V. et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 372, 1700-1709 (2015
29. Cross, D.A. et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4, 1046-1061 (2014
30. Cragg, M.S. et al. Treatment of BRAF-mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J. Clin. Invest. 118, 3651-3659 (2008
31. Corcoran, R.B. et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models. Cancer Cell 23, 121-128 (2013
32. de Bruin, E.C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256 (2014
33. McGranahan, N. & Swanton, C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27, 15-26 (2015
34. Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S. & Bardelli, A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 4, 1269-1280 (2014
35. Maheswaran, S. et al. Detection of mutations in EGFR in circulating lung cancer cells. N. Engl. J. Med. 359, 366-377 (2008
36. Byers, L.A. et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR-inhibitor resistance. Clin. Cancer Res. 19, 279-290 (2013
37. Hirata, E. et al. Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin-β1 and FAK signaling. Cancer Cell 27, 574-588 (2015
38. Ramirez, et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat. Commun. (in the press
39. Thress, K.S. et al. Acquired EGFRC797S mutation mediates resistance to AZD9291 in non-small-cell lung cancer harboring EGFRT790M. Nat. Med. 21, 560-562 (2015
40. Niederst, M.J. et al. RB loss in resistant EGFR-mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat. Commun. 6, 6377 (2015
41. Misale, S. et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci. Transl. Med. 6, 224ra26 (2014
42. Dias-Santagata, D. et al. Rapid targeted mutational analysis of human tumors: a clinical platform to guide personalized cancer medicine. EMBO Mol. Med. 2, 146-158 (2010
43. Hata, A.N. et al. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Res. 74, 3146-3156 (2014
44. Chmielecki, J. et al. Optimization of dosing for EGFR-mutant non-small-cell lung cancer with evolutionary cancer modeling. Sci. Transl. Med. 3, 90ra59 (2011
45. Tyson, D.R., Garbett, S.P., Frick, P.L. & Quaranta, V. Fractional proliferation: a method to deconvolve cell population dynamics from single-cell data. Nat. Methods 9, 923-928 (2012
46. Kunkel, T.A. & Bebenek, K. DNA replication fidelity. Annu. Rev. Biochem. 69, 497-529 (2000
47. Oller, A.R., Rastogi, P., Morgenthaler, S. & Thilly, W.G. A statistical model to estimate variance in long-term, low-dose mutation assays: testing of the model in a human lymphoblastoid mutation assay. Mutat. Res. 216, 149-161 (1989
48. Alexandrov, L.B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013
49. Lynch, M. Rate, molecular spectrum and consequences of human mutation. Proc. Natl. Acad. Sci. USA 107, 961-968 (2010
50. Lawrence, M.S. et al. Mutational heterogeneity in cancer and the search for new cancer-Associated genes. Nature 499, 214-218 (2013
51. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 (2013
52. Anders, S., Pyl, P.T. & Huber, W. HTSeq-A Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166-169 (2015
53. Robinson, M.D., McCarthy, D.J. & Smyth, G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene-expression data. Bioinformatics 26, 139-140 (2010
54. Subramanian, A. et al. Gene-set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005
55. Mootha, V.K. et al. PGC-1?-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267-273 (2003